Metabolic disease is already dramatically more prevalent among people living with schizophrenia than in the general population — a disparity that shortens lives by decades and remains poorly understood. New evidence now implicates something surprisingly modifiable: how much artificial light patients are exposed to while they sleep. This finding adds a circadian dimension to a largely pharmacological conversation about metabolic risk in serious mental illness.
The LENS study enrolled 222 outpatient adults diagnosed with schizophrenia and used objective, wrist-worn actigraphy combined with bedside photometers across seven consecutive nights — a methodological strength over self-reported measures. After controlling for confounders, individuals in the highest quartile of nighttime illuminance carried more than four times the odds of obesity (OR 4.01), more than three times the odds of hypertension (OR 3.38), and roughly 2.4 times the odds of dyslipidemia compared to those in the lowest quartile. While no statistically significant association emerged for diabetes diagnosis per se, higher nighttime light levels correlated meaningfully with elevated glycosylated hemoglobin — a marker of longer-term glycemic dysregulation.
This work sits at the intersection of two growing literatures: research linking light-at-night to circadian disruption and metabolic dysfunction in the general population, and the well-established observation that antipsychotic medications independently raise cardiometabolic risk. What remains unresolved — and is a key limitation of this cross-sectional design — is causality. Patients with more severe illness or worse sleep architecture may simply be exposed to more nighttime light incidentally, rather than light being the mechanistic driver. The cohort size of 222, while sufficient for association analysis, limits subgroup inference. Still, the dose-response pattern across quartiles strengthens the biological plausibility. If replicated in longitudinal work, environmental light management could represent one of the few low-cost, non-pharmacological levers for reducing cardiovascular burden in this chronically underserved population.